Molecular Therapeutics – Trademark Portfolio
Entity Type: 13
Molecular Therapeutics holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include TRICIDE, NEOCIDE-3, and SILVAKLENZ. The owner is based in Athens, GA.
425 River Rd, Suite 422
Athens, GA 30602
Showing of trademarks Trademarks
Trademark Classifications
Molecular Therapeutics's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does Molecular Therapeutics have?
Molecular Therapeutics has 9 U.S. trademarks filed with the USPTO. Of these, 3 registered, 2 abandoned, 4 cancelled.
What trademark classes does Molecular Therapeutics file in?
Molecular Therapeutics files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Molecular Therapeutics's most well-known trademarks?
Molecular Therapeutics's registered trademark portfolio includes well-known marks such as TRICIDE, NEOCIDE-3, and SILVAKLENZ. These are among 3 currently registered trademarks in the portfolio.
What is Molecular Therapeutics's trademark registration success rate?
Molecular Therapeutics has a 33% trademark registration rate, with 3 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.